>If Intergel has been available for a few years in some European
>countries, then there must be some statistics on its performance for
>those years. Does anyone know how its working out?
Okay, my memory was a little off (you hit 40 and everything does go downhill) from when I read these articles before but it's only been available for about a year and a half. So most, if not all, studies will probably be those already mentioned on lifecore's site.
CHASKA, MN. May 5, 1998-- LIFECORE BIOMEDICAL, INC. (Nasdaq:LCBM) announced today that it has shipped its first commercial order of INTERGEL™Adhesion Prevention Solution to Ethicon, Inc., a Johnson & Johnson Company. INTERGEL™ Adhesion Prevention Solution is a proprietary surgical solution indicated for use in the reduction of postsurgical adhesions after certain abdominal surgeries. The product will be marketed for Lifecore by Ethicon on an exclusive worldwide basis. Initial European sales will commence during the June quarter in France, Germany, Italy, and the United Kingdom. The rest of Europe and other non-U.S. sites will follow on a graduated basis. U.S. sales are estimated to begin in late 1999, pending timely U.S. premarket approval (PMA) by the Food and Drug Administration. Lifecore expects to begin the U.S. PMA filing process for INTERGEL™ Solution by the end of June. The Company estimates that it could receive U.S. market approval by the end of 1999.